

IAS-ILF THEMATIC ROUNDTABLE ON KEY POPULATIONS

24 February 2015
Seattle, Washington, USA

Evaluation report




Introduction

To complement the work of the International AIDS Society's (IAS's) Key Populations (KPs) Priority, the IAS's Industry Liaison Forum (ILF) held a thematic roundtable on Key Populations. The event provided a space for a multi-stakeholder dialogue, serving as the basis to inform about the situation (i.e., raise mutual awareness), quantify the size of the problems, and discuss interventions and organizations that can support existing efforts for wider access to HIV services. This includes the creation of an enabling environment to end stigma and discrimination for these difficult-to-reach populations and communities. The agenda is available in Appendix A. The information presented in this report is a summary of results from the online survey of participants (see Appendix B), providing feedback and criticisms to better conduct future events.









Attendance

A total of 53 people participated in the meeting. Seventeen people (32%) participated in the survey; all attended the meeting in person. Seven were from non-governmental organizations, five were from industry (the majority involved with antiretrovirals, ARVs), three were from academia and two were from other organizations.




Feedback from participants


Participants were asked to rate the usefulness of different aspects of the meeting.



Participants were asked what they gained from this meeting. The majority stated that they gained new contacts, opportunities for collaboration and new information. Of the respondents who said that they gained new contacts, 92% (12/13) said that they were planning to follow up with these new contacts.



Participants were also asked what they believed would be the best way for the ILF to follow up on the roundtable. Most chose the continued protocol option (59%), while many suggested other approaches including a “meeting with presentations from industry partners”, “working groups to translate ideas into action”, “something that is more action focussed vs discussion focussed”, and “a similar discussion at the IAS meetings open to more people”.



Participants were asked what could be done to improve future roundtables. Many participants suggested that the length of the meeting be cut down to shorter intervals, that there be fewer presentations, and that more time be allowed for discussion between participants (including suggestions for the meeting to run over one or two days).

Participants were asked how industry could be further engaged in supporting key populations. A variety of answers were provided. Many respondents believed that increasing education between partners, whether through more workshops and meetings or via seminars, would provide the necessary information to engage the support that is needed. Other respondents also suggested collaborations with generic manufacturers. Selected quotations are provided here:

“Find some way to hear more from generic manufacturers, since they provide the major part of HIV treatment for KPs (in resource-limited countries now, and globally soon).”


“Providing support for workshops and meetings to address issues related to [KPs]; partnering with international and national organizations to define products, interventions, and strategies for addressing needs of [KPs]; accelerating development of technologies, such as long-acting formulations or point-of-care diagnostics, that can address needs of [KPs]; and facilitating regulatory approvals and policies that will foster uptake and utilization of new technologies.”

“Make industry aware of the role that KPs play in creating markets for their products and the advantage of communicating with them.”


“More structured engagement to explore and elaborate possible collaborations.”

Additional suggestions included “[having] more social networking time”, “focusing more on specific initiatives”, “planning on how to disseminate [the information and meeting outcomes] to the general membership, since attendance [is] restricted”, “[sending] meeting objectives to participants beforehand”, “priming non-industry participants to come to the meeting beforehand with clear, discrete, projects that could help move the needle for prevention and care for KPs”, “[assembling] a white paper that provides separate recommendations for PEPFAR and [the] Global Fund”, “[including] more [KPs] participation [in these meetings]” and “[avoiding to] tokenize participation of KPs”.

Participants were then asked if, prior to this meeting, they were aware of the ILF and the IAS Priority on Key Populations. Most of the respondents were aware of only one of the two programmes.



Participants were then asked which conferences they usually attended. Every respondent of the survey (100%) said that they attended the International AIDS Conference. The second most commonly attended event was the Conference on Retroviruses and Opportunistic Infections (76%), closely followed by the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (12/17 people: 71%).



Overall, this thematic roundtable was received positively. The criticisms that came from the survey were focused on the excessive length and late starting time.

THEMATIC ROUNDTABLE ON KEY POPULATIONS

Organized by the International AIDS Society Industry Liaison Forum and Key Populations Priority

Tuesday, 24 February 2015, 18:00–22:30 PST · 2201 Westlake Avenue #200 (PATH), Seattle, WA, USA

18:00-18:30	Light dinner buffet	
18:30-18:45	Welcome and roundtable introduction <i>Kenneth Mayer (Fenway Institute, USA) – IAS-ILF Co-Chair</i> <i>Manuel Gonçalves (ViiV Healthcare, UK) – IAS-ILF Co-Chair</i>	
18:45-19:00	Overview presentation I: KPs — demographics, epidemiology and epidemic drivers <i>Gottfried Hirschall (WHO HIV/AIDS Department, Switzerland)</i>	Facts
19:00-19:20	Overview presentation II: The cascade for HIV prevention, diagnosis and treatment in the context of discrimination <i>Chris Beyrer (Johns Hopkins University, USA) – IAS President</i>	Barriers
19:20-20:25	Panel discussion: Best current practices to reaching KPs <i>Moderator: Kevin Frost (amfAR, USA)</i> <i>Panellist / PWIDs: Holly Bradford (INPUD, USA)</i> <i>Panellist / Sex workers: Frances Cowan (CeSHHAR, Zimbabwe)</i> <i>Panellist / Transgender people: JoAnne Keatley (UCSF, USA)</i> <i>Panellist / Young KPs: Thaw Zin Aye (Youth LEAD, Thailand)</i> <i>Panellist / MSM: Nikos Dedes (Positive Voice, Greece)</i> <i>Clarifying Questions</i> <i>Panellist / Diagnostics: Duncan Blair (Alere, Thailand)</i> <i>Panellist / Treatment: Paul Schaper (MSD, USA)</i> <i>Panellist / Prevention: James Rooney (Gilead Sciences, USA)</i> <i>Panellist / Prevention: Gustavo Doncel (CONRAD, USA)</i> <i>Clarifying Questions</i>	Challenges
20:25-21:45	Roundtable discussion: Innovative approaches to meeting the 90-90-90 UNAIDS goals for KPs <ul style="list-style-type: none"> • <i>Programming and policies</i> • <i>Access to prevention, diagnostics, treatment and care</i> • <i>Stigma and discrimination</i> • <i>Financing and accountability</i> • <i>Technology</i> <i>Facilitator: Chris Collins (UNAIDS, Switzerland)</i>	Solutions
21:45-22:00	Summary: Challenges and opportunities <i>Kenneth Mayer (Fenway Institute, USA) – IAS-ILF Co-Chair</i> <i>Manuel Gonçalves (ViiV Healthcare, UK) – IAS-ILF Co-Chair</i> <i>Sébastien Morin (IAS, Switzerland) – IAS-ILF Research Officer</i>	
22:00-22:30	Cocktail / Reception	

Appendix B: Survey (page 1 of 2)

Thank you for participating to the recent ILF/CIPHER Thematic Roundtable on Paediatric ARVs. Your contribution was deeply appreciated.

In order for the Industry Liaison Forum and CIPHER to follow up in the most appropriate manner, please share your feedback through our online survey.

1. How useful would you rate the different parts of the meeting?
(1-10 – 1: not useful, 10: very useful)
 - a. Welcome and roundtable introduction
 - b. Overview presentation 1: KPs — demographics, epidemiology and epidemic drivers
 - c. Overview presentation II: The cascade for HIV prevention, diagnosis and treatment in the context of discrimination
 - d. Panel discussion: Best current practices to reaching KPs
 - e. Roundtable discussion: Innovative approaches to meeting the 90-90-90 UNAIDS goals for KPs
 - f. Summary: Challenges and opportunities
 - g. Informal reception

2. What did you gain from attending this meeting? Please select all that apply.
 - a. New information on HIV and key populations
 - b. New ideas
 - c. Opportunities for collaboration
 - d. New contacts
 - i. Will you follow up on these new contacts?
 - Yes
 - No
 - I don't know
 - e. Nothing

3. What in your view would be the best way for the IAS to follow up on this roundtable? Please select all that apply.
 - a. Continue with the same format (multi-stakeholder roundtable discussion)
 - b. White paper
 - c. Webinar series (closed, with same participants)
 - d. Webinar series (open to anyone)
 - e. I don't know
 - f. Other ideas (please explain below)

4. Please suggest any improvements for future roundtables (e.g. duration, location, issues to be covered or stakeholders to be invited).

Appendix B: Survey (page 2 of 2)

5. Please suggest how you think industry can further be engaged in supporting key populations.

6. Before this meeting, were you aware of the IAS Industry Liaison Forum and the IAS Priority on Key Populations?

- a. Yes (both)
- b. Partly (only the Industry Liaison Forum)
- c. Partly (only the priority on Key Populations)
- d. No

7. Do you have any additional comments, suggestions, and/or questions?

8. What type of organization do you work for?

- a. Community-based organization
- b. Academia
- c. Hospital / clinic
- d. Governmental organization
- e. Non-governmental organization
- f. Industry – ARVs
- g. Industry – Diagnostics
- h. Industry – Prevention
- i. Industry – Other
- j. Other

9. Which events do you generally attend?

- a. Conference on Retroviruses and Opportunistic Infections (CROI)
- b. European AIDS Clinical Society Conference (EACS)
- c. HIV Drug Therapy Glasgow
- d. HIV Drug Therapy in the Americas
- e. IAS Conference on HIV Pathogenesis, Treatment and Prevention
- f. International AIDS Conference
- g. International Congress on AIDS in Asia and the Pacific (ICAAP)
- h. International Conference on AIDS and Sexually Transmitted Infections in Africa (ICASA)
- i. Social Aspects of HIV/AIDS Research Alliance (SAHARA)
- j. Others

10. How did you attend the meeting?

- In person
- Through WebEx
 - i. Please rate your experience. (*excellent, good, fair, poor*)

International AIDS Society

Avenue de France 23
CH-1202 Geneva
Switzerland

Tel: +41 22 710 08 00
Fax: +41 22 710 08 99

ias@iasociety.org
www.iasociety.org

